Glucagon‐like Peptide-1 Agonists and Smoking Cessation: A Brief Review

By: Robbins RA

Abstract: The glucagon‐like peptide 1 (GLP-1) agonists such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®) have shown efficacy inducing weight loss in both diabetics and non-diabetics. According to the incentive sensitization theory of addiction, these drugs may prove useful in addictive disorders such as nicotine addiction. Animal data has been suggestive of a potential positive effect but early human studies have been mixed. This manuscript reviews the theory of addiction as well as the few animal and human studies available. Further human studies are needed to show GLP-1 agonist efficacy in smoking cessation.

URL: /pulmonary/2024/11/5/glucagonlike-peptide-1-agonists-and-smoking-cessation-a-brie.html